Trial · NCT02930005
Pentosan Polysulfate Sodium and Meclofenamic Acid as Treatments in Patients With Psychotic Disorders
NCT02930005, Phase 2, Completed, The University of Texas Health Science Center, Houston; results first posted 2019-03-26
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pentosan Polysulfate Sodium and Meclofenamic Acid as Treatments in Patients With Psychotic Disorders. Trials, record NCT02930005. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02930005
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pentosan Polysulfate Sodium and Meclofenamic Acid as Treatments in Patients With Psychotic Disorders
- NCT number
- NCT02930005
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 8 participants, actual
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Conditions
- Psychotic Disorders, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Interventions
- Meclofenamic acid, Pentosan polysulfate sodium
- First posted
- 2016-10-11
- Last updated
- 2019-03-26
- Results first posted
- 2019-03-26
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Cognitive Function as Assessed by the NIH Toolbox Cognitive Test Battery (NCTB) Composite Score | baseline, 8 weeks | A higher composite score on the NCTB indicates better cognitive performance. The NCTB consists of 7 tests and 8 sub-scores, and the NIH Toolbox software calculates total composite score by averaging the normalized scores of each subscale and then deriving scale scores. The "NIH Toolbox Scoring and Interpretation Guide" (found online) doesn't indicate a total composite score range (because the score ranges are infinite), but describes scoring as follows: To get a normalized composite score, the score of the test taker is compared to the scores in the NIH Toolbox nationally representative normative sample. The mean score is 100 and the standard deviation (SD) is 15. A score at or near 100 indicates average ability compared with others. Scores around 115 suggest above-average ability. Scores around 130 suggest superior ability (in the top 2 percent nationally). A score around 85 suggests below-average ability. A score in the range of 70 or below suggests significant impairment. |
| Secondary | Change in Severity of Psychotic Symptoms as Assessed by Positive and Negative Syndrome Scale (PANSS) | baseline, 8 weeks | Change in the Positive and Negative Syndrome Scale (PANSS) total score after 8 weeks. The range of scores on the PANSS is 30 to 210, with higher scores associated with better outcomes. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Cognitive Function as Assessed by the NIH Toolbox Cognitive Test Battery (NCTB) Composite Score | baseline, 8 weeks | score | NUMBER | |
| SECONDARY | Change in Severity of Psychotic Symptoms as Assessed by Positive and Negative Syndrome Scale (PANSS) | baseline, 8 weeks | score | NUMBER |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Cognitive Function as Assessed by the NIH Toolbox Cognitive Test Battery (NCTB) Composite Score | Meclofenamic Acid | 31.96 | score | ||
| Change in Cognitive Function as Assessed by the NIH Toolbox Cognitive Test Battery (NCTB) Composite Score | Pentosan Polysulfate Sodium | 0.96 | score | ||
| Change in Severity of Psychotic Symptoms as Assessed by Positive and Negative Syndrome Scale (PANSS) | Meclofenamic Acid | -11 | score | ||
| Change in Severity of Psychotic Symptoms as Assessed by Positive and Negative Syndrome Scale (PANSS) | Pentosan Polysulfate Sodium | -22 | score |
Source ClinicalTrials.gov
Participant flow8
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Meclofenamic Acid | 2 | |
| Overall Study | STARTED | Pentosan Polysulfate Sodium | 6 | |
| Overall Study | Completed 2 Weeks | Meclofenamic Acid | 2 | |
| Overall Study | Completed 2 Weeks | Pentosan Polysulfate Sodium | 2 | |
| Overall Study | COMPLETED | Meclofenamic Acid | 1 | |
| Overall Study | COMPLETED | Pentosan Polysulfate Sodium | 1 | |
| Overall Study | NOT COMPLETED | Meclofenamic Acid | 1 | |
| Overall Study | NOT COMPLETED | Pentosan Polysulfate Sodium | 5 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Hyperglycemia | Endocrine disorders | Meclofenamic Acid | 0 | 2 | 0 |
| other | Hyperglycemia | Endocrine disorders | Pentosan Polysulfate Sodium | 1 | 6 | 1 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Meclofenamic Acid | 0 | 2 |
| Total, all-cause mortality | Pentosan Polysulfate Sodium | 0 | 6 |
| Total, other adverse events | Meclofenamic Acid | 0 | 2 |
| Total, other adverse events | Pentosan Polysulfate Sodium | 1 | 6 |
| Total, serious adverse events | Meclofenamic Acid | 0 | 2 |
| Total, serious adverse events | Pentosan Polysulfate Sodium | 0 | 6 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Meclofenamic Acid vs Pentosan Polysulfate Sodium: deaths from any cause | Trial comparisons |
| Meclofenamic Acid vs Pentosan Polysulfate Sodium: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02930005
GET https://conductscience.org/api/trials/v1/NCT02930005/registered